

Introduction to Session: Meningococcal Vaccines

Jamie Loehr, MD
Chair, ACIP Meningococcal/Hib Vaccines Work Group

June 28, 2024

ACIP Meningococcal/Hib Vaccines Work Group

- ACIP Members on the WG
 - Jamie Loehr (Chair)
 - Wilbur Chen
- Ex Officio WG Members
 - Margaret Bash (FDA)
 - Matthew Clark (IHS)
 - Xin-Xing Gu (NIH)
- WG Liaisons and Consultants
 - Amra Resic (AAFP)
 - Mary Healy (AAP)
 - Barb Fluty (ACHA)
 - Karyn Lyons (AIM)
 - Paul Cieslak (CSTE)
 - Kathy Hsu (IDSA)
 - Pamela Doyon-Plourde (NACI)
 - Jeff Goad (NFID)
 - Jessica Cataldi (PIDS)
 - Amy Middleman (SAHM)
 - Kathy Poehling (Wake Forest)
 - Lynn Bahta (Minnesota Department of Health)
 - David Stephens (Emory)
- GRADE/EtR Support
 - Doug Campos-Outcalt (Arizona)
 - Rebecca Morgan (Case Western Reserve)
- CDC Contributors
 - Sarah Schillie (DBD/NCIRD)
 - Jennifer Collins (DBD/NCIRD)
 - Lucy McNamara (DBD/NCIRD)
 - LeAnne Fox (DBD/NCIRD)
 - Susan Hariri (DBD/NCIRD)
 - Amy Rubis (DBD/NCIRD)
 - Noele Nelson (DBD/NCIRD)
 - Alison Albert (DBD/NCIRD)
 - Shelby Miller (DBD/NCIRD)
 - Michelle Hughes (DBD/NCIRD)
 - Brian Edwards (DBD/NCIRD)
 - Isha Berry (DBD/NCIRD)
 - Madhura Vachon (DBD/NCIRD)
 - Gabrielle Cooper (DBD/NCIRD)
 - Xiaoyu Dong (ISD/NCIRD)
 - Andrew Leidner (ISD/NCIRD)
 - Ismael Ortega-Sanchez (CORVD/NCIRD)
 - Liz Velazquez (ISD/NCIRD)
 - Marc Fischer (DIDRI/NCEZID)
 - Jonathan Duffy (DHQP/NCEZID)
 - Pedro Moro (DHQP/NCEZID)
 - Tanya Myers (DHQP/NCEZID)
 - Leslie Lee (OD/NCIRD)
 - Manisha (Mo) Patel (OD/NCIRD)
 - Jessica MacNeil (ACIP Secretariat)
 - Hannah Rosenblum (ACIP Secretariat)
 - Melinda Wharton (ACIP Secretariat)

Two Terms of Reference

- GSK's MenABCWY Vaccine
- Revisiting the adolescent meningococcal vaccine schedule

Today's agenda

Topic	Presenter
Epidemiology Updates	Ms. Amy Rubis (CDC/NCIRD)
GSK Pentavalent Vaccine Immunogenicity and Safety	Dr. Wendy Sohn (GSK)
Work Group Considerations Regarding MenABCWY Vaccine and Discussion of Potential Risk Groups for MenB Vaccination	Dr. Sarah Schillie (CDC/NCIRD)

All topics will be presented for information and discussion

Policy Questions for GSK's MenABCWY (Pentavalent) Vaccine

- Should the pentavalent vaccine be included as an option for MenACWY/MenB vaccination in people currently recommended to receive both vaccines at the same visit?
 - For example, 16 year-olds*
- Should the pentavalent vaccine be included as an option for people currently recommended to receive MenACWY only?
 - For example, 11–12 year-olds
- Should the pentavalent vaccine be included as an option for people currently recommended to receive MenB only?
 - For example, during a serogroup B outbreak

*16 year-olds who receive the MenB vaccine based on shared clinical decision-making

Upcoming ACIP Meetings

- October 2024
 - GRADE/EtR
 - Cost-effectiveness analysis
- February 2025
 - Anticipated Vote